期刊名称：DRUGS & AGING
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Drugs & Aging provides you with authoritative and current information on drug use in the aging population as well as diseases of the aging and the effects of aging on drug treatment.
By providing peer reviewed, impartial and reliable data, the review articles in Drugs & Aging assist you in making clinical decisions and treatment choices based on international consensus, keeping you well informed on important issues, up to date with emerging treatments, and aware of the place of specific drugs in therapy.
Aims & Scope
The Journal aims to promote optimum drug therapy in older adults by providing a regular programme of review articles covering the most important aspects of clinical pharmacology and patient management in this unique group. Physiological changes during aging which have implications for drug therapy also fall within the scope of the Journal.
Specific topics within these broad subject areas are presented as either comprehensive literature reviews which provide an assessment of the overall findings, shorter and more practically oriented review articles which are adequately supported by literature citations, brief leading articles which address emerging areas in an overview fashion, or articles discussing current opinion on controversial topics. Original research articles are considered for publication.
Instructions to Authors
For Information for Authors please click here.
Please also review the Editorial Policies and Procedures for Review and Original Research Articles for the Adis International Review Journals. For information on Adis Drug Evaluations, please review the appropriate policies page.
Instruction for authors
Submission of original research to all International Review Journals with the exception of Drugs is encouraged.
Suggestions for article topics (and potential authors) for consideration by the editors and editorial boards are welcome at any time. If you are interested in preparing a review, please contact the journal with your proposed outline to confirm suitability. You should also review the policy statements for review articles and original research and Adis Drug Evaluations and Adis Drug Profiles.
The following PDF documents contain instructions and information for the preparation and layout of documents for submissi
Original Research
All Adis International Review Journals, aside from Drugs, consider Original Research Articles for publication.
Please refer to the Instructions for Authors of the specific journal you are interested in to determine the desired article types.
Current Opinion
A Current Opinion article should be a succinct commentary on the topic proposed, not an exhaustive review. The overall objective is to place in perspective an area of current international interest that may be controversial, and for this reason personal opinion, clearly identified as such, is welcome. The arguments presented may be controversial, but at the same time must be balanced and rational. In addition, the article should be of international scope.
Therapy in Practice
The intention of a Therapy in Practice article is to provide a succinct, clinically orientated guide to management of a particular disease or condition. The article need not be heavily referenced, although important points and definitive statements should be supported by appropriate literature citations. There is room for some personal opinion if it is clearly identified as such. However, the internationally accepted consensus on appropriate therapeutic guidelines should be the aim.
Leading Article
A Leading Article should be a short, balanced review of a relatively small literature base, typically of a new or developing topic, that should provide an overview of the current state of development of the area being written about. The article should be fully referenced and of international scope.
Review Article
The Review Article should be an authoritative, comprehensive and critical review of the literature, reflecting the current state of accepted international medical practice or clinical research in a particular area. The article must present a balanced, rather than personal, review of the literature, and should be fully referenced. Wherever possible, literature should be evaluated rather than simply restated. Furthermore, all therapies of relevance to the topic should be discussed in order to provide full coverage of the spectrum of agents used in the disease area or drug category under discussion.
Reference Style Guide
References are required to support all significant statements. They are also used to indicate the origin of material (quotations, tables, figures), and as a source for research and further reading. They need to be given in a form where the reader can quickly and easily identify the correct reference and locate the material in a library or on a database.
Our referencing system is based on the 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals' (the 'Vancouver' style), with some minor modifications.
It is important to adhere to the style set out here (e.g. superior numbers inside square brackets in the text), which will facilitate processing.
Specific Journal Variations
Clinical Drug Investigation
All articles in Clinical Drug Investigation are submitted.
Information on the content, formatting and layout of articles for submission is available in this PDF.
Call for Papers
see pdf
Why use Pharmaceutical Reprints?
Reprints are an excellent, cost-effective tool for one-to-one marketing, conferences and seminars, sales rep support and mailing new product information to a wide audience.
You can use Pharmaceutical reprints to:
distribute to conference delegates in packs or on your stand
as a door-opener for sales reps
support new product launches and product development
update target audiences with your key messages
disseminate information on your product to a wider audience.
Permission:
Requests for permission to photocopy, republish or mount Adis material on either an intranet or internet site should be sent via mail, fax or email to:
Permissions for UK, Europe and rest of world:
Corey Eberhart
Pharma Licensing Manager, Europe Asia-Pacific
Wolters Kluwer Health
Lippencott Williams & Wilkins
351 W Camden Street
Baltimore, MD 21201
USA
ceberhar@lww.com
Fax: +1 410 528 4331
Permissions for USA:
Kristin Mobley
Adis International
860 Town Center Drive
Langhorne
PA19047
USA
kristin.mobley@adis.com
Fax: +1 215 741 2502
- W.S. Aronow, Bronx, NY, USA
- S. Bank, New Hyde Park, NY, USA
- J. Belmin, Sevran, France
- G. Bianchi Porro, Milan, Italy
- G. Crepaldi, Padova, Italy
- B.J. Cusack, Boise, ID, USA
- J.-M. Dayer, Geneva, Switzerland
- F.T. Fraunfelder, Portland, OR, USA
- K. Ghose, Dunedin, New Zealand
- M. Gordon, Toronto, ON., Canada
- D.J. Greenblatt, Boston, MA, USA
- W.B. Kannel, Boston, MA, USA
- R. Kawamori, Tokyo, Japan
- S.R. Kraus, San Antonio, TX, USA
- A.J. Krentz, Southampton, England
- H. Lode, Berlin, Germany
- D.E. Meier, New York, NY, USA
- J.S. Meyer, Houston, TX, USA
- A.D. Mooradian, St Louis, MO, USA
- R.S. Norrby, Lund, Sweden
- D.M. Prinsley, Kew, Victoria, Australia
- B.J. Sahakian, Cambridge, England
- C.G. Swift, London, England
- C.J. van Boxtel, Amsterdam, The Netherlands
- R.E. Vestal, San Francisco, CA, USA
- R.W. Warne, Perth, WA, Australia
- M.E. Weksler, New York, NY, USA
Editorial Board
Editorial Staff
Editor: Amitabh Prakash
Publication Manager: Melanie Thorburn
E-mail:journalDRA@adis.co.nz
|
